Why focal hip cartilage defects are difficult to treat without surgery

A scan that reveals a focal cartilage defect in the hip raises a question that symptom-relief injections cannot fully answer: what can be done about the defect itself, not just the pain around it?

Hip articular cartilage has no meaningful blood supply. Once a discrete area breaks down to the underlying bone — what clinicians classify as a Grade III or IV focal defect — the tissue has almost no capacity to heal on its own. Left untreated, mechanical loading can gradually widen the lesion, even in a hip that has otherwise healthy surrounding cartilage and years of useful life ahead of it.

This is where focal defects sit awkwardly in the treatment landscape. They are not the same as end-stage osteoarthritis, where cartilage is absent across the entire joint surface and hip replacement becomes the logical next step. Yet they are also beyond what symptom-management options can address structurally. Corticosteroid and hyaluronic acid injections may reduce pain and improve comfort, but neither intervenes at the defect itself — the underlying cartilage gap remains.

Filling that gap requires something that can both occupy the defect space and support the body's own repair biology. A combination of a cell-retaining scaffold and a concentrated source of the patient's own progenitor cells addresses precisely that — recruiting repair cells and anchoring them within the lesion rather than simply bathing the wider joint in anti-inflammatory or lubricating fluid.

How ChondroFiller™ works as an injectable collagen scaffold

Injected directly into a focal hip cartilage defect under ultrasound guidance, ChondroFiller™ is an acellular gel composed of murine-derived Type I collagen — the same structural protein the body uses to build connective tissue. It holds CE marking as a Class III medical device, meaning it has passed the regulatory rigour required for implantable products in contact with human tissue. Liquid Cartilage™ is the clinical brand name applied to this same product and pathway.

The key behaviour is what happens once the gel meets the defect environment: it sets in situ within minutes, bonding to the surrounding cartilage walls and forming a structured three-dimensional matrix. This is not a permanent implant — it is a temporary scaffold designed to be progressively replaced by the patient's own tissue.

The mechanism is best described as acellular matrix-induced chondrogenesis. Rather than delivering laboratory-grown cells, ChondroFiller™ recruits the patient's own progenitor cells from the adjacent synovium and subchondral bone. These cells migrate into the scaffold, receive the biochemical cues encoded in the collagen matrix, and begin differentiating towards a chondrocyte-like phenotype. As the repair tissue matures over the following months, the collagen scaffold biodegrades, leaving fibrocartilage-like tissue where the defect previously sat.

Because the gel sets rapidly without requiring a dry joint field, it can be placed in the hip under image guidance in an outpatient setting — no general anaesthetic or surgical admission is needed.

What BMAC contains and why it supports cartilage repair

BMAC stands for Bone Marrow Aspirate Concentrate. It is drawn from the iliac crest — the rim of the pelvis — using a needle under local anaesthetic, a process that takes roughly twenty minutes in an outpatient setting. The aspirate is then spun in a centrifuge to concentrate the cellular and growth-factor fraction before use. There is no surgical incision involved.

What the centrifuge concentrates matters. BMAC contains mesenchymal stem cells (MSCs) carrying cell-surface markers CD90+, CD73+, and CD271+, which identify them as progenitor cells capable of differentiating into chondrocytes under the right conditions. Alongside these cells, the concentrate delivers a growth-factor payload — TGF-β1/2, BMP-2, PDGF, VEGF, and bFGF — that synergistically promotes chondrogenesis. PDGF in particular may help suppress IL-1β, an inflammatory mediator implicated in progressive cartilage breakdown.

Because BMAC is drawn from the patient's own marrow and processed without laboratory expansion, it is classified as a minimally manipulated autologous product. This distinction matters clinically: it allows BMAC to be used without the additional regulatory approval burden that applies to culture-expanded cell therapies.

Two caveats apply. Cellular concentration within BMAC varies with harvesting technique and patient factors, so yield is not uniform. Optimal dosing for hip cartilage repair specifically has not yet been established in the literature; in practice, dosing decisions are made by the treating clinician at assessment, guided by defect characteristics and the marrow yield obtained.

The cell-retention problem: why the two products are used together

The hip joint is a sealed, fluid-filled space. Synovial fluid circulates continuously, and cells or growth factors injected freely into the cavity are likely to be diluted and dispersed before they can engraft at the defect site. This is the practical problem with delivering BMAC to the hip without an anchoring vehicle: the therapeutic payload may never reach — or remain at — the lesion it is intended to repair.

ChondroFiller™ addresses this through its physical behaviour in situ. Once placed within the defect, the collagen gel sets rapidly, creating a three-dimensional matrix that traps co-delivered BMAC cells and growth factors within the defect space rather than allowing them to wash away into the surrounding joint fluid. Its primary role in this pairing is therefore retention — holding the cellular payload precisely where cartilage repair needs to occur — not simply adding a second regenerative layer.

The combination is mechanistically additive rather than duplicative. ChondroFiller™ provides the architecture, the chemotactic signals, and the physical containment; BMAC contributes the MSC population and the growth-factor payload — TGF-β, BMP-2, PDGF, and the rest — that drives differentiation within that scaffold.

Single-stage scaffold-plus-cell procedures have published precedent: Gobbi et al. reported good long-term outcomes using a hyaluronic acid scaffold combined with BMAC-sourced MSCs (HA-BMAC), with medium-term results comparable to two-stage cell-based techniques. That work supports the conceptual basis for combining scaffold and cells in a single procedure. Hip-specific outcome data for this particular product pairing is still maturing, so the precedent should be read as conceptual support rather than direct proof of equivalence.

What the treatment involves at Lincolnshire Hip

For most patients, the entire visit takes place in a single outpatient appointment at Lincolnshire Hip's clinics in Grantham or Sleaford — no general anaesthetic, no overnight admission, no surgical theatre.

The session opens with the BMAC draw: a small marrow aspirate from the iliac crest, taken under local anaesthetic and spun chairside in a centrifuge to produce the concentrated cellular fraction. While that is being prepared, the hip is positioned and the target site confirmed with ultrasound. Both products — the BMAC concentrate and ChondroFiller™ — are then co-delivered under image guidance directly into the focal cartilage defect. Ultrasound visualisation allows accurate placement within the defect space, reducing the risk of dispersal into the wider joint cavity.

Patients are typically discharged the same day with written guidance. A protected loading period of approximately four to six weeks follows — reduced weight-bearing and restricted hip range of motion while the collagen scaffold integrates and the cellular payload establishes within the defect. Repair tissue builds gradually from around three to six months post-procedure, and structural change can be confirmed on follow-up MRI where that level of monitoring is clinically appropriate.

The standalone ChondroFiller™ injection — suitable for eligible focal hip defects — is available at both clinics at a guide price of £2,995 per injection, which covers the full outpatient visit including consultation, image-guided placement, and the implant itself. Patients whose defect characteristics indicate the combined Liquid Cartilage™ pathway would be assessed individually, with the treatment plan and pricing confirmed at that stage.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for hip assessment.

Who this is suitable for and what the evidence currently shows

Patient selection shapes the likelihood of benefit more than almost any other factor. The clearest candidates are those with an isolated, focal Grade III or IV hip cartilage defect — meaning a well-defined area of damage with healthy cartilage at its margins rather than diffuse wear across the joint surface. End-stage hip disease, where articular cartilage is broadly absent, falls outside the indication for either product.

Early-stage disease also matters for BMAC specifically. Published series suggest patients with lower-grade joint involvement respond better, and those with advanced joint-space loss are more likely to require hip arthroplasty even after BMAC treatment.

What the evidence currently shows

For ChondroFiller™ in the hip, published data reports a mean Harris Hip Score improvement of approximately +33 points, covering focal hip cartilage damage and femoroacetabular impingement. Across joint applications, MOCART MRI scores range from 70 to 87, with structural defect filling progressing from a mean of 65.3 at four weeks to 81.6 at one year. More than 19,000 procedures have been performed globally, with a reported complaint rate of approximately 0.06%.

For the specific combination of BMAC co-delivered with ChondroFiller™ in the hip, no published prospective RCT yet exists. Most BMAC cartilage evidence derives from knee studies; scaffold-plus-BMAC precedent (including the Gobbi et al. HA-BMAC series discussed earlier) supports the mechanistic rationale but does not directly confirm long-term hip outcomes for this product pairing. That is the current state of a maturing field rather than a reason to dismiss the approach — the biological logic is sound, and hip-specific registry data continues to accumulate.

A specialist assessment remains the appropriate next step for anyone who fits the broad criteria above, to confirm defect characteristics, joint-space status, and overall suitability before any treatment decision is made.